Geron Corp (NASDAQ:GERN)

CAPS Rating: 2 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Results 1 - 20 of 158 : 1 2 3 4 5 6 7 8 Next »

Recs

0
Member Avatar oncqueen (67.51) Submitted: 4/3/2014 11:57:03 AM : Outperform Start Price: $2.02 GERN Score: +14.97

This is a very promising drug that is delayed, not dead, and is trading at left-for-dead prices. I'm going to buy some in the real world, too.

Recs

0
Member Avatar fwstash (< 20) Submitted: 1/24/2014 12:50:31 PM : Outperform Start Price: $5.67 GERN Score: -66.98

So what I see is that after having a failed drug and trimming the company's output was smart money. Focusing on a drug that has been treating and working towards a true cure, total remission, get's me excited. As this year progressives Geron will succeed only to the amount the CEO allows, possible a sellout but hopeful for a merge.

Recs

0
Member Avatar BMunkers (49.16) Submitted: 12/30/2013 8:14:47 PM : Outperform Start Price: $4.79 GERN Score: -56.89

Did you know that the hole's natural enemy is the pile?

Recs

0
Member Avatar LexSC (31.99) Submitted: 12/6/2013 4:34:49 PM : Outperform Start Price: $5.90 GERN Score: -67.94

This a gamble on my part. If the drug they are developing pans out, they can name their price. If not this is a cheap strike out.

Recs

0
Member Avatar cavemantrader (47.73) Submitted: 11/7/2013 11:18:51 AM : Outperform Start Price: $6.75 GERN Score: -75.81

GERN is unique developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Company also has zero debt which is a plus. This will surprise to the upside in a big way.

Recs

2
Member Avatar fatmoneyrz (96.13) Submitted: 10/16/2013 10:29:14 PM : Outperform Start Price: $4.05 GERN Score: -55.11

I've got a mysterious vibe about GERN. When I was walking the city streets very early this morning a fortune teller on a small side street drew me in and wanted to read my palms. While doing so I looked into her crystal ball and saw big $$$, pleasure yachts and Lear jets, and also the letters GERN. The fortune teller stated great wealth was in my future, and stated fundamentals and valuation didn't matter-- that I would buy something that would shoot up to an astronomical degree-- much like a company called ACAD, and I would know it when I saw it. When the market opened this morning I bought GERN.

Recs

2
Member Avatar zzlangerhans (99.69) Submitted: 8/16/2013 12:07:37 AM : Underperform Start Price: $1.52 GERN Score: -42.29

Geron spiked up a little on rather vague descriptions of progress made in the IST of imetelstat for myelofibrosis but I maintain this one surviving indication for one surviving pipeline candidate doesn't merit an enterprise value of more than 100M.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:35:50 PM : Underperform Start Price: $1.34 GERN Score: -63.73

Short. Essentially no revenues. Burning through cash rapidly

Recs

0
Member Avatar LouisAIrl (< 20) Submitted: 9/10/2012 11:55:00 AM : Outperform Start Price: $1.25 GERN Score: +55.77

Down too much today

Recs

0
Member Avatar KimLanners (< 20) Submitted: 11/15/2011 7:18:24 PM : Underperform Start Price: $1.68 GERN Score: +14.37

down

Recs

0
Member Avatar Terbius (< 20) Submitted: 9/3/2011 2:39:47 PM : Outperform Start Price: $2.60 GERN Score: -79.77

stem cell research is the most promising new medical technology

Recs

0
Member Avatar StockDoc (< 20) Submitted: 8/27/2011 2:52:54 PM : Outperform Start Price: $2.58 GERN Score: -71.57

Phase 2 study results pending and multi[le applications with core research should push to new highs

Recs

0
Member Avatar GTcollegekid (27.06) Submitted: 7/9/2011 10:21:24 AM : Outperform Start Price: $4.35 GERN Score: -93.31

stem cell

Recs

0
Member Avatar bddc4 (< 20) Submitted: 5/12/2011 12:14:28 PM : Outperform Start Price: $4.97 GERN Score: -98.52

stem cells are the future in medicine.

Recs

0
Member Avatar Kenergy (87.57) Submitted: 5/11/2011 4:25:22 AM : Outperform Start Price: $6.11 GERN Score: -122.99

Give this 12 - 18 months and it will be $50/share. The down side or the depressing side is that it will trade between $5.25 and $4.70 until the day it takes off. 12% chance it fails.

Recs

0
Member Avatar segundo100 (< 20) Submitted: 3/19/2011 9:24:59 PM : Outperform Start Price: $4.87 GERN Score: -103.16

Their current biomedical research has great potential, the next uptrend pike should not be far from now.

Recs

0
Member Avatar getupstandup (< 20) Submitted: 2/13/2011 9:16:27 PM : Outperform Start Price: $5.15 GERN Score: -101.64

when i saw the article on the national news about the mouse that walked after treatment ,i looked to see if they were in a stock market and immediately purchased 6000 shares and have since then bought an additional 3000 . my take is simple what has worked in mice has worked in men plus the fact that i seemto have a knack for picking winners and this little gem is such a bargan at even 5 or 6 dollars yhat if this flys its going to go so high so fast your going to get a nose bleed.

Recs

0
Member Avatar lipripper (< 20) Submitted: 12/2/2010 9:29:26 PM : Outperform Start Price: $5.86 GERN Score: -120.58

this one I believe has a big growth story waiting on it-Im in at 5.74

Recs

0
Member Avatar ragar200 (85.50) Submitted: 11/26/2010 2:46:34 PM : Outperform Start Price: $5.72 GERN Score: -124.54

cleared for fda clinical trials

Recs

0
Member Avatar doublepedro (< 20) Submitted: 11/24/2010 10:35:34 PM : Outperform Start Price: $5.75 GERN Score: -123.84

Geron has developed a very broad, high-caliber pipeline and IP portfolio (please check out the company's website for specifics). The company has made significant prgress into early and mid-stage clinical trials on multiple fronts in Oncology and Regenerative Medicine. Geron's IP/pipeline represents a paradigm shift in the way human disease is treated. As such, progress has been a bit slower than may ordinarily be seen in development stage biotechs (and has understandably tested the patience of long-time investors). Nonetheless, with great risk comes (hopefully) great reward and all told Geron has done a remarkable job navigating largely uncharted terriitory in order to bring multiple programs in its pipeline into clinical trials (and against difficult market conditions over the last 10 years, no less). The company is starting to realize limited revenues from technology it co-developed with partners like GE Healthcare and Corning for scalable GMP cell culturing. This revenue won't fund the company but it will help with the need to raise additional capital as it moves to later stage (and eventually pivotal) clinical trials.

Although Geron's near and mid-term future has never looked better, it still represents a speculative investment. However, the breadth, depth and potential of its IP/pipeline make for compelling valuation in a company with a $600M market cap. I think its valuation is sufficently compelling to make a speculative investment with a long-term horizon. It wouldn't surprise me if a larger pharmaceutical company felt similarly. If so, current investors may be rewarded sooner than they might otherwise would have expected.

Featured Broker Partners


Advertisement